NCT00001785View on ClinicalTrials.gov

Recombinant Human Interferon Beta-1a (Avonex) for the Treatment of Patients With HTLV-1-Associated Myelopathy (HAM)

PHASE2CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

September 30, 1998

Study Completion Date

September 30, 2004

Conditions

HTLV-I InfectionSpinal Cord DiseaseTropical Spastic Paraparesis

Interventions

DRUG

Recombinant human interferon beta-1a

Trial Locations (1)

20892

National Institute of Neurological Disorders and Stroke (NINDS), Bethesda

All Listed Sponsors

lead

National Institute of Neurological Disorders and Stroke (NINDS)

NIH

NCT00001785 - Recombinant Human Interferon Beta-1a (Avonex) for the Treatment of Patients With HTLV-1-Associated Myelopathy (HAM) | Biotech Hunter | Biotech Hunter